Edesa Biotech Receita T/T
Qual é o Receita T/T de Edesa Biotech?
O Receita T/T de Edesa Biotech, Inc. é N/A
Qual é a definição de Receita T/T?
O crescimento trimestral da receita, ano após ano, é o aumento da receita de uma empresa em comparação com o desempenho no trimestre correspondente do ano anterior, expresso como uma porcentagem.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
O que Edesa Biotech faz?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.